A5005148708- Radiopharmaceutical Chemistry and Applications
- Chemical Reactions and Isotopes
- PARP inhibition in cancer therapy
- Advanced biosensing and bioanalysis techniques
- Bacteriophages and microbial interactions
- Nanoparticle-Based Drug Delivery
- Cancer Immunotherapy and Biomarkers
- Advanced Biosensing Techniques and Applications
- Synthesis and Biological Evaluation
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- interferon and immune responses
- Monoclonal and Polyclonal Antibodies Research
Bayer (Germany)
2021-2023
Background Targeted thorium-227 conjugates (TTCs) are an emerging class of targeted alpha therapies (TATs). Their unique mode action (MoA) is the induction difficult-to-repair clustered DNA double-strand breaks. However, thus far, their effects on immune system largely unknown. Here, we investigated immunostimulatory mesothelin-targeted conjugate (MSLN-TTC) in vitro and vivo monotherapy combination with inhibitor checkpoint programmed death receptor ligand 1 (PD-L1) immunocompetent mice....
Targeted alpha therapies (TAT) are an innovative class of for cancer treatment. The unique mode-of-action TATs is the induction deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as gynecologic cancers upregulating chemoresistance P-glycoprotein (p-gp) and overexpressing membrane protein mesothelin (MSLN), promising targets TATs. Here, based on previous encouraging findings with monotherapy, we investigated efficacy mesothelin-targeted thorium-227 conjugate (MSLN-TTC)...
<p>Supplementary Tables and Supplementary Methods</p>
<div>Abstract<p>Targeted alpha therapies (TATs) are an innovative class of for cancer treatment. The unique mode-of-action TATs is the induction deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as gynecological cancers upregulating chemoresistance P-glycoprotein (p-gp) and overexpressing membrane protein mesothelin (MSLN), promising targets TATs. Here, based on previous encouraging findings with monotherapy, we investigated efficacy mesothelin-targeted...
<p>Supplementary Tables and Supplementary Methods</p>
<div>Abstract<p>Targeted alpha therapies (TAT) are an innovative class of for cancer treatment. The unique mode-of-action TATs is the induction deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as gynecologic cancers upregulating chemoresistance P-glycoprotein (p-gp) and overexpressing membrane protein mesothelin (MSLN), promising targets TATs. Here, based on previous encouraging findings with monotherapy, we investigated efficacy mesothelin-targeted...
<p>Supplementary Tables and Supplementary Methods</p>
<p>Supplementary Tables and Supplementary Methods</p>
<div>Abstract<p>Targeted alpha therapies (TATs) are an innovative class of for cancer treatment. The unique mode-of-action TATs is the induction deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as gynecological cancers upregulating chemoresistance P-glycoprotein (p-gp) and overexpressing membrane protein mesothelin (MSLN), promising targets TATs. Here, based on previous encouraging findings with monotherapy, we investigated efficacy mesothelin-targeted...
<p>Supplementary Tables and Supplementary Methods</p>
<p>Supplementary Tables and Supplementary Methods</p>
<div>Abstract<p>Targeted alpha therapies (TAT) are an innovative class of for cancer treatment. The unique mode-of-action TATs is the induction deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as gynecologic cancers upregulating chemoresistance P-glycoprotein (p-gp) and overexpressing membrane protein mesothelin (MSLN), promising targets TATs. Here, based on previous encouraging findings with monotherapy, we investigated efficacy mesothelin-targeted...
Abstract Mesothelin-targeted thorium-227 conjugate (MSLN-TTC) is a targeted alpha therapeutic consisting of MSLN-targeting antibody anetumab covalently attached to 3,2-HOPO chelator complexed with the emitter thorium-227. It has potent in vivo activity cell and patient-derived xenograft (PDX) models monotherapy combination DNA damage repair inhibitors. We evaluated antitumor efficacy MSLN-TTC mesothelin overexpressing ovarian PDX model (ST206B) bevacizumab or multikinase inhibitor...
Abstract Targeted thorium-227 conjugates (TTCs) represent a new class of targeted alpha therapy (TAT). TTCs consist an antigen targeting moiety, which is covalently attached to 3,2-HOPO chelator, enabling specific complexation and delivery the particle emitter tumor cells. have demonstrated potent preclinical in vivo activity monotherapy combination with DNA damage inhibitors. In present work, immunostimulatory effects mesothelin (MSLN) conjugate (MSLN-TTC) was studied immunocompetent mice,...